GTX/UX Diluent and Flush Solution
Sponsors
Ultragenyx Pharmaceutical Inc.
Conditions
Angelman Syndrome
Phase 2
Phase 3
A Long-Term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome
RecruitingCTIS2024-510917-14-00
Start: 2024-09-03Target: 38Updated: 2025-11-14
A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome
RecruitingCTIS2024-512600-19-00
Start: 2025-04-14Target: 40Updated: 2025-09-19